In recent years, the field of neuroimaging dramatically moved forward by means of the
expeditious development of specific radioligands of novel targets. Among these targets, the …

PET technology has produced many radiopharmaceuticals that target specific brain proteins
and other measures of brain function. Recently, a new approach has emerged to image …

Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by
a CAG trinucleotide expansion in the huntingtin (HTT) gene that encodes the pathologic …

The development of novel radiotracers for Positron Emission Tomography (PET) imaging
agents targeting the synaptic vesicle glycoprotein 2 A (SV2A), an integral glycoprotein …

At present, spinal cord imaging primarily uses magnetic resonance imaging (MRI) or
computed tomography (CT), but the greater sensitivity of positron emission tomography …

It is unknown whether alterations in EEG brain activity caused by Huntington's disease may
be responsive to huntingtin-lowering treatment. We analysed EEG recordings of 46 patients …

The development of novel PET imaging agents for synaptic vesicle glycoprotein 2A (SV2A)
allowed for the in vivo detection of synaptic density changes, which are correlated with the …

Neurodevelopmental disorders (NDDs) are a group of complex neurologic and psychiatric
disorders. Functional and molecular imaging techniques, such as resting-state functional …

Traumatic spinal cord injury (SCI) is a neurologic condition characterized by long-term motor
and sensory neurologic deficits as a consequence of an external physical impact damaging …

Huntington's disease (HD) is a rare, autosomal, and dominantly inherited
neurodegenerative disease characterized by aggregation of mutated Huntingtin protein …